Lurasidone Showed Promise for Cannabis-Induced Psychosis in Four Young Patients
Four patients experiencing their first cannabis-induced psychotic episode were treated with lurasidone (74-128 mg/day), and all showed improvement in positive and negative symptoms, disruptive behavior, and functioning with no significant side effects.
Quick Facts
What This Study Found
All four patients improved across psychosis symptoms (positive and negative), disruptive behavior, and functional recovery. Target lurasidone doses ranged from 74-128 mg/day. No significant side effects were reported.
Key Numbers
4 patients with first cannabis-induced psychotic episodes. Lurasidone doses: 74-128 mg/day. All showed remission of positive and negative symptoms, reduced disruptive behavior, and return of functioning. No significant side effects reported.
How They Did This
Case series of four patients with first-episode cannabis-induced psychosis treated with lurasidone at a single center. Clinical improvement was assessed across multiple symptom domains.
Why This Research Matters
Cannabis-induced psychosis is increasingly common, but there is limited evidence on optimal antipsychotic choice. Lurasidone may be particularly suitable due to its favorable metabolic and sedation profile, which matters for young patients.
The Bigger Picture
First-episode psychosis often occurs in young people where medication side effects (weight gain, sedation, metabolic problems) can be particularly problematic. Lurasidone's relatively clean side-effect profile makes it an appealing option that deserves formal testing.
What This Study Doesn't Tell Us
Only four patients, no control group, single center. Case reports cannot establish efficacy. The improvement may reflect natural recovery from a self-limited psychotic episode rather than medication effect. No long-term follow-up reported.
Questions This Raises
- ?Would a randomized trial comparing lurasidone to other atypical antipsychotics confirm its advantages for cannabis-induced psychosis?
- ?What is the optimal duration of treatment?
- ?Does lurasidone affect cannabis use behavior itself?
Trust & Context
- Key Stat:
- All 4 patients achieved remission on lurasidone 74-128 mg/day
- Evidence Grade:
- Preliminary: uncontrolled case series of only four patients.
- Study Age:
- Published in 2022.
- Original Title:
- Lurasidone use in Cannabis-Induced Psychosis: A Novel Therapeutic Strategy and Clinical Considerations in Four Cases Report.
- Published In:
- International journal of environmental research and public health, 19(23) (2022)
- Authors:
- Ricci, Valerio(14), Martinotti, Giovanni(18), De Berardis, Domenico(9), Maina, Giuseppe
- Database ID:
- RTHC-04168
Evidence Hierarchy
Describes what happened to one person or a small group.
What do these levels mean? →Frequently Asked Questions
What is the best medication for cannabis-induced psychosis?
There is limited evidence to identify a best option. This case series suggests lurasidone may be effective with a favorable side-effect profile, but formal clinical trials are needed to compare it to other antipsychotics.
Is cannabis-induced psychosis the same as schizophrenia?
Not necessarily. Cannabis-induced psychosis is triggered by cannabis use and may resolve with abstinence. However, some cases may represent the unmasking of an underlying psychotic vulnerability, particularly in people with genetic risk.
Read More on RethinkTHC
- THC-amygdala-anxiety-brain
- anandamide-weed-withdrawal
- cannabinoid-receptors-recovery-time
- cannabis-developing-brain-teenagers
- cant-enjoy-anything-without-weed
- dopamine-recovery-after-quitting-weed
- endocannabinoid-system-explained-simply
- endocannabinoid-system-withdrawal
- nervous-system-weed-withdrawal-fight-flight
- teen-weed-use-under-18-effects-brain
- thc-brain-withdrawal
- thc-prefrontal-cortex-brain-effects
- weed-cortisol-stress-hormones
- weed-memory-loss-recovery
- weed-motivation-amotivational-syndrome
- weed-nervous-system-effects
- weed-reward-system-brain
Cite This Study
https://rethinkthc.com/research/RTHC-04168APA
Ricci, Valerio; Martinotti, Giovanni; De Berardis, Domenico; Maina, Giuseppe. (2022). Lurasidone use in Cannabis-Induced Psychosis: A Novel Therapeutic Strategy and Clinical Considerations in Four Cases Report.. International journal of environmental research and public health, 19(23). https://doi.org/10.3390/ijerph192316057
MLA
Ricci, Valerio, et al. "Lurasidone use in Cannabis-Induced Psychosis: A Novel Therapeutic Strategy and Clinical Considerations in Four Cases Report.." International journal of environmental research and public health, 2022. https://doi.org/10.3390/ijerph192316057
RethinkTHC
RethinkTHC Research Database. "Lurasidone use in Cannabis-Induced Psychosis: A Novel Therap..." RTHC-04168. Retrieved from https://rethinkthc.com/research/ricci-2022-lurasidone-use-in-cannabisinduced
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.